CHEK1 and Miyoshi myopathy: Further, higher CHEK1 expression was associated with poor outcome in the TT2 (Fig. 1B), HOVON65 (Fig. 1C), and GMMG-HD (Figure S1) patient cohorts, which included over 1200 MM patients.